Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2015

01.12.2015 | review

Clinical utility of circulating tumor DNA in human cancers

verfasst von: Ellen Heitzer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

The use of circulating tumor DNA (ctDNA) as a prognostic and/or predictive biomarker has been proven in numerous studies. Recent technical advancements have improved sensitivity, specificity, and feasibility of ctDNA detection enabling innovative clinical applications. Besides its potential use as a diagnostic biomarker and the detection of recurrence or minimal residual disease, the most widespread application of the so-called liquid biopsy is real-time monitoring of treatment response and tumor evolution. Since tissue biopsies provide just a static snapshot of the tumor at the time of biopsy and do not necessarily represent the entire tumor genome, a sequential analysis of ctDNA enables an early identification of resistance mechanisms before they become clinically obvious. Furthermore, novel therapy targets that have not been present in available tumor samples might be identified. However, for an actual implementation of the liquid biopsy in clinical practice, it is essential to develop standardized pre-analytical and analytical methodologies and to resolve some outstanding question with respect to origin, biology, and dynamics of ctDNA. In this short review, the clinical utility and existing limitations of ctDNA focusing on monitoring treatment response will be discussed.
Literatur
1.
Zurück zum Zitat Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014;11(7):432–8. PubMed PMID: 24687035. PubMedCrossRef Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014;11(7):432–8. PubMed PMID: 24687035. PubMedCrossRef
2.
Zurück zum Zitat Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational Implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258–66. PubMed PMID: 25770293. Pubmed Central PMCID: 4374162. PubMedPubMedCentralCrossRef Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational Implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258–66. PubMed PMID: 25770293. Pubmed Central PMCID: 4374162. PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Gerlinger M. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. PubMedCrossRef Gerlinger M. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. PubMedCrossRef
4.
Zurück zum Zitat Mandel PMP. Les acides nucleiques du plasma sanguin chez l’homme [in French]. Seances Soc Biol Fil. 1948;142:241–3. Mandel PMP. Les acides nucleiques du plasma sanguin chez l’homme [in French]. Seances Soc Biol Fil. 1948;142:241–3.
5.
Zurück zum Zitat Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50. PubMed PMID: 837366. PubMed Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50. PubMed PMID: 837366. PubMed
6.
Zurück zum Zitat Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23. PubMed PMID: 25388429. PubMedCrossRef Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23. PubMed PMID: 25388429. PubMedCrossRef
7.
Zurück zum Zitat Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? Future Oncol. 2014;10(3):417–28. PubMed PMID: 24559448. PubMedCrossRef Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? Future Oncol. 2014;10(3):417–28. PubMed PMID: 24559448. PubMedCrossRef
8.
Zurück zum Zitat Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. PubMed PMID: 24449238. Epub 2014/01/23. Eng. PubMedCrossRef Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. PubMed PMID: 24449238. Epub 2014/01/23. Eng. PubMedCrossRef
9.
Zurück zum Zitat Gonzalez-Masia JA, Garcia-Olmo D, Garcia-Olmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 2013;6:819–32. PubMed PMID: 23874104. Pubmed Central PMCID: 3711950. PubMedPubMedCentral Gonzalez-Masia JA, Garcia-Olmo D, Garcia-Olmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 2013;6:819–32. PubMed PMID: 23874104. Pubmed Central PMCID: 3711950. PubMedPubMedCentral
10.
Zurück zum Zitat Kim K, Shin DG, Park MK, Baik SH, Kim TH, Kim S, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86(3):136–42. PubMed PMID: 24761422. Epub 2014/04/25. Eng. PubMedPubMedCentralCrossRef Kim K, Shin DG, Park MK, Baik SH, Kim TH, Kim S, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86(3):136–42. PubMed PMID: 24761422. Epub 2014/04/25. Eng. PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014;146(1):163–74. PubMed PMID: 24838941. PubMedCrossRef Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014;146(1):163–74. PubMed PMID: 24838941. PubMedCrossRef
12.
Zurück zum Zitat Chen X. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res. 1999;5:2297–303. PubMed Chen X. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res. 1999;5:2297–303. PubMed
13.
Zurück zum Zitat Sozzi G. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–8. PubMed Sozzi G. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–8. PubMed
14.
Zurück zum Zitat Arnalich F, Menendez M, Lagos V, Ciria E, Quesada A, Codoceo R, et al. Prognostic value of cell-free plasma DNA in patients with cardiac arrest outside the hospital: an observational cohort study. Crit Care. 2010;14(2):R47. PubMed PMID: 20350299. Pubmed Central PMCID: 2887159. PubMedPubMedCentralCrossRef Arnalich F, Menendez M, Lagos V, Ciria E, Quesada A, Codoceo R, et al. Prognostic value of cell-free plasma DNA in patients with cardiac arrest outside the hospital: an observational cohort study. Crit Care. 2010;14(2):R47. PubMed PMID: 20350299. Pubmed Central PMCID: 2887159. PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care. 2006;10(2):R60. PubMed PMID: 16613611. Pubmed Central PMCID: 1550922. PubMedPubMedCentralCrossRef Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care. 2006;10(2):R60. PubMed PMID: 16613611. Pubmed Central PMCID: 1550922. PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. PubMed PMID: 24553385. Epub 2014/02/21. Eng. PubMedPubMedCentralCrossRef Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. PubMed PMID: 24553385. Epub 2014/02/21. Eng. PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 2014;16(4):421. PubMed PMID: 25107527. PubMedPubMedCentralCrossRef Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 2014;16(4):421. PubMed PMID: 25107527. PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013;133(2):346–56. PubMed PMID: 23319339. Pubmed Central PMCID: 3708119. PubMedPubMedCentralCrossRef Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013;133(2):346–56. PubMed PMID: 23319339. Pubmed Central PMCID: 3708119. PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Thierry AR, Mouliere F, Messaoudi SE, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430–5. PubMed PMID: 24658074. Epub 2014/03/25. Eng. PubMedCrossRef Thierry AR, Mouliere F, Messaoudi SE, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430–5. PubMed PMID: 24658074. Epub 2014/03/25. Eng. PubMedCrossRef
20.
Zurück zum Zitat Misale S. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. PubMedPubMedCentral Misale S. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. PubMedPubMedCentral
21.
Zurück zum Zitat Kuo YB, Chen JS, Fan CW, Li YS, Chan EC. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–9. PubMed PMID: 24685572. PubMedCrossRef Kuo YB, Chen JS, Fan CW, Li YS, Chan EC. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–9. PubMed PMID: 24685572. PubMedCrossRef
22.
Zurück zum Zitat Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10(3):e1004271. PubMed PMID: 24676216. Pubmed Central PMCID: 3967949. PubMedPubMedCentralCrossRef Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10(3):e1004271. PubMed PMID: 24676216. Pubmed Central PMCID: 3967949. PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Diaz LA Jr. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–40. PubMedPubMedCentral Diaz LA Jr. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–40. PubMedPubMedCentral
24.
Zurück zum Zitat Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002;22:421–5. PubMed Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002;22:421–5. PubMed
25.
Zurück zum Zitat Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26(4):731–6. PubMed PMID: 25628445. Pubmed Central PMCID: 4374387. PubMedCrossRef Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26(4):731–6. PubMed PMID: 25628445. Pubmed Central PMCID: 4374387. PubMedCrossRef
26.
Zurück zum Zitat Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013;5(4):30. PubMed PMID: 23561577. Pubmed Central PMCID: 3707016. PubMedPubMedCentralCrossRef Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013;5(4):30. PubMed PMID: 23561577. Pubmed Central PMCID: 3707016. PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90. PubMed PMID: ISI:000258988600033. English. PubMedPubMedCentralCrossRef Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90. PubMed PMID: ISI:000258988600033. English. PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–209. PubMed PMID: 23484797. PubMedCrossRef Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–209. PubMed PMID: 23484797. PubMedCrossRef
29.
Zurück zum Zitat Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–12. PubMed PMID: 23563269. PubMedCrossRef Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–12. PubMed PMID: 23563269. PubMedCrossRef
30.
Zurück zum Zitat Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra154. PubMed PMID: 23197571. Pubmed Central PMCID: 3641759. PubMedPubMedCentral Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra154. PubMed PMID: 23197571. Pubmed Central PMCID: 3641759. PubMedPubMedCentral
31.
Zurück zum Zitat Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2015. PubMed PMID: 25654990. Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2015. PubMed PMID: 25654990.
32.
Zurück zum Zitat Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25(10):1959–65. PubMed PMID: 25185240. PubMedCrossRef Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol. 2014;25(10):1959–65. PubMed PMID: 25185240. PubMedCrossRef
33.
Zurück zum Zitat Bratman SV, Newman AM, Alizadeh AA, Diehn M. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-SEq. Expert Rev Mol Diagn. 2015;16:1–5. PubMed PMID: 25773944. CrossRef Bratman SV, Newman AM, Alizadeh AA, Diehn M. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-SEq. Expert Rev Mol Diagn. 2015;16:1–5. PubMed PMID: 25773944. CrossRef
34.
Zurück zum Zitat Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54. PubMed PMID: 24705333. Epub 2014/04/08. Eng. PubMedPubMedCentralCrossRef Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54. PubMed PMID: 24705333. Epub 2014/04/08. Eng. PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015;6(4):2549–61. PubMed PMID: 25575824. PubMedPubMedCentralCrossRef Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015;6(4):2549–61. PubMed PMID: 25575824. PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA. 2015;112(11):E1317–25. PubMed PMID: 25646427. Pubmed Central PMCID: 4372002. PubMedPubMedCentralCrossRef Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA. 2015;112(11):E1317–25. PubMed PMID: 25646427. Pubmed Central PMCID: 4372002. PubMedPubMedCentralCrossRef
Metadaten
Titel
Clinical utility of circulating tumor DNA in human cancers
verfasst von
Ellen Heitzer
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0217-5